Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Return on Invested Capital (2019 - 2025)

VYNE Therapeutics (VYNE) has disclosed Return on Invested Capital for 7 consecutive years, with 1.03% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Return on Invested Capital changed N/A year-over-year to 1.03%, compared with a TTM value of 1.03% through Jun 2025, changed N/A, and an annual FY2025 reading of 0.75%, down 13.0% over the prior year.
  • Return on Invested Capital was 1.03% for Q2 2025 at VYNE Therapeutics, down from 0.94% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.54% in Q2 2021 and bottomed at 2.69% in Q1 2021.
  • Average Return on Invested Capital over 5 years is 1.12%, with a median of 0.94% recorded in 2025.
  • The sharpest move saw Return on Invested Capital skyrocketed 508bps in 2021, then tumbled -133bps in 2023.
  • Year by year, Return on Invested Capital stood at 0.72% in 2021, then crashed by -34bps to 0.96% in 2022, then tumbled by -120bps to 2.11% in 2023, then surged by 64bps to 0.75% in 2024, then plummeted by -36bps to 1.03% in 2025.
  • Business Quant data shows Return on Invested Capital for VYNE at 1.03% in Q2 2025, 0.94% in Q1 2025, and 0.75% in Q4 2024.